ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0903

Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis

Emil Rydell1, Lennart Jacobsson2 and Carl Turesson3, 1Lund University, Malmö, Sweden, 2Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Cardiovascular, Inflammation, Outcome measures, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD). Systemic inflammation, driven by cytokines such as TNF, IL-6 and IL-17A, has been implicated as a contributing factor to CVD development in RA. The objective of this study was to investigate the impact of 92 inflammatory proteins on the risk of CVD events in patients with early RA.

Methods: Consecutive patients with early RA patients (symptom duration < 12 months), recruited 1995-2005 from a defined area, were followed in an observational study. Stored plasma samples from the baseline visit were analyzed for levels of 92 inflammatory proteins (Inflammation panel by O-link). Data on CVD events (coronary-, cerebrovascular- and peripheral artery disease) were retrieved from the Swedish national inpatient- and cause of death registries from 1969-2019. Statistical analyses were pre-designated as hypothesis-driven (Table 1) or exploratory. For the latter, principal component analysis was used to identify groups of proteins that explain the variance in the proteome. Within components selected based on Eigenvalues, proteins with a factor loading of >0.50 were investigated as potential predictors of CVD events. Protein levels were standardized to facilitate comparison. Patients with CVD events before RA diagnosis were excluded from the analyses. Primary outcome was the first CVD event, and secondary outcome was the first coronary artery disease (CAD) event during follow-up. Cox regression models (crude and age-sex adjusted) were used to assess the relationship between baseline biomarkers and outcomes. Models with significant predictors were further adjusted for ESR, to assess independent inflammatory pathways. For a priori hypothesis-based analyses, multiple testing was taken into account using Holm’s correction.

Results: Baseline levels of proteins were available for 163 patients. A first ever CVD event occurred in 47 patients during follow-up, and a first ever CAD event in 37 patients. Among potential biomarkers with an a priori hypothesis, levels of IL-17A were significantly associated with overall CVD events in the crude and age-sex adjusted models (Table 1), and when additionally adjusted for baseline levels of ESR [adjusted hazard ratio 1.34; 95% confidence interval 1.03-1.76), while the associations did not reach significance for CAD events (Table 1). Osteoprotegerin (OPG) levels were significantly associated with both outcomes in crude, but not in adjusted models (Table 1). There were no such associations for IL-6, TNF, Monocyte Chemotactic Protein (MCP) 1 or IL-8 (Table 1). In the exploratory analyses, several proteins, in particular MCP-3, had significant associations with CVD and CAD events, but only in the unadjusted models (Table 2).

Conclusion: Plasma levels of IL-17A at RA diagnosis predicted future CVD events,
although we cannot exclude that this finding is due to multiple testing. The observed association was
independent of levels of systemic inflammation, measured by ESR, suggesting a particular role for IL-17A in mechanisms leading to CVD. OPG and MCP-3 may also be predictive of CVD in patients with RA and should be further investigated.

Supporting image 1

Supporting image 2


Disclosures: E. Rydell, None; L. Jacobsson, Novartis, Eli Lilly, Janssen; C. Turesson, AbbVie/Abbott, Nordic Drugs, Bristol-Myers Squibb(BMS).

To cite this abstract in AMA style:

Rydell E, Jacobsson L, Turesson C. Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/plasma-inflammatory-protein-biomarkers-may-predict-cardiovascular-events-in-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-inflammatory-protein-biomarkers-may-predict-cardiovascular-events-in-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology